Oncotarget

Research Papers:

MicroRNA expression levels as diagnostic biomarkers for intraductal papillary mucinous neoplasm

Lei Wang, Jianming Zheng, Chang Sun, Li Wang, Gang Jin, Lei Xin, Zhendong Jin, Dong Wang and Zhaoshen Li _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:58765-58770. https://doi.org/10.18632/oncotarget.17679

Metrics: PDF 1720 views  |   HTML 2657 views  |   ?  


Abstract

Lei Wang1,*, Jianming Zheng2,*, Chang Sun1,*, Li Wang3, Gang Jin4, Lei Xin1, Zhendong Jin1, Dong Wang1 and Zhaoshen Li1

1Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China

2Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China

3Department of Radiology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China

4Department of General Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China

*These authors have contributed equally to this study

Correspondence to:

Zhaoshen Li, email: [email protected]

Keywords: intraductal papillary mucinous neoplasms (IPMNs), miRNA, cancer diagnosis

Received: January 23, 2017    Accepted: March 10, 2017    Published: May 08, 2017

ABSTRACT

Intraductal papillary mucinous neoplasms (IPMNs) are deadly exocrine mucinous tumors. Currently the molecular features and diagnostic markers of IPMNs are not well understood. In this study, we performed microRNA (miRNA) profiling assays to study the potential roles of miRNAs in IPMNs using 78 cases of IPMN patients and controls. When comparing the miRNA expression between IPMN patient samples and controls, we found that miR-210, miR-223, miR-221, miR-155 and miR-187 were differentially expressed in normal pancreas and IPMNs. We further studied the miRNA expression profiles in different pancreatic diseases and identified miRNA features that are associated with Chronic pancreatitis (CP), IPMN, and Pancreatic ductal adenocarcinoma (PDAC). Therefore, these miRNAs might serve as new risk biomarkers of IPMN and could be useful for future targeted therapies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17679